This invention encompasses an antimicrobial that can treat diseases caused by the pathogen Neisseria Gonorrhoeae (Ngo). The compounds described can be incorporated into commercially available personal lubricants for individual use.
N. gonorrhoeae (Ngo) causes over 160 million new cases of gonorrhea each year globally; in 2018, it caused 1.6 million new infections in the US. This bacterial pathogen primarily infects the urogenital tract and oropharynx of men and women. It also establishes asymptomatic infections at high frequency; up to 60% of cervical infections are asymptomatic. Ngo has quickly developed resistance to all but one antibiotic used for its treatment. No new antibiotics against Ngo are in the drug development pipeline, and there is no gonorrhea vaccine. The NIH, the CDC, and WHO therefore list Ngo as a pathogen of great concern and stress the need to develop new anti-gonococcal antibiotics and antimicrobial agents.
- Therapeutic option for treating bacterial disease
- Microbicide against Ngo
- Ease of delivery
- Highly effective
- Prevent transmission
TTO Home Page: https://arizona.technologypublisher.com
Name: Michelle Albert
Title: IP Docket Clerk